

ORION MEDTECH LTD C.I.C.

**Company Registration Number:
11589078 (England and Wales)**

Unaudited statutory accounts for the year ended 31 May 2020

Period of accounts

Start date: 1 October 2019

End date: 31 May 2020

ORION MEDTECH LTD C.I.C.

Contents of the Financial Statements for the Period Ended 31 May 2020

Directors report

Profit and loss

Balance sheet

Additional notes

Balance sheet notes

Community Interest Report

ORION MEDTECH LTD C.I.C.

Directors' report period ended 31 May 2020

The directors present their report with the financial statements of the company for the period ended 31 May 2020

Principal activities of the company

The principal activity of the company during the period was that of providing information technology services.

Directors

The directors shown below have held office during the whole of the period from
1 October 2019 to 31 May 2020

Dr P.H. Jarritt
Pr J.D.P. Pickard
Dr A. Joannides

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
26 May 2021

And signed on behalf of the board by:

Name: Dr A. Joannides
Status: Director

ORION MEDTECH LTD C.I.C.

Profit And Loss Account for the Period Ended 31 May 2020

	<i>8 months to 31 May 2020</i>	<i>2019</i>
	£	£
Turnover:	204,768	41,580
Cost of sales:	(152,511)	
Gross profit(or loss):	<u>52,257</u>	<u>41,580</u>
Administrative expenses:	(10,668)	(16,642)
Operating profit(or loss):	<u>41,589</u>	<u>24,938</u>
Profit(or loss) before tax:	<u>41,589</u>	<u>24,938</u>
Tax:	(7,902)	(4,766)
Profit(or loss) for the financial year:	<u>33,687</u>	<u>20,172</u>

ORION MEDTECH LTD C.I.C.

Balance sheet

As at 31 May 2020

	<i>Notes</i>	<i>8 months to 31 May 2020</i>	<i>2019</i>
		£	£
Current assets			
Cash at bank and in hand:		79,537	36,788
Total current assets:		<u>79,537</u>	<u>36,788</u>
Creditors: amounts falling due within one year:	3	(24,678)	(15,616)
Net current assets (liabilities):		<u>54,859</u>	<u>21,172</u>
Total assets less current liabilities:		<u>54,859</u>	<u>21,172</u>
Total net assets (liabilities):		<u>54,859</u>	<u>21,172</u>
Capital and reserves			
Called up share capital:		1,000	1,000
Profit and loss account:		53,859	20,172
Total Shareholders' funds:		<u>54,859</u>	<u>21,172</u>

The notes form part of these financial statements

ORION MEDTECH LTD C.I.C.

Balance sheet statements

For the year ending 31 May 2020 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

**This report was approved by the board of directors on 26 May 2021
and signed on behalf of the board by:**

Name: Dr A. Joannides
Status: Director

The notes form part of these financial statements

ORION MEDTECH LTD C.I.C.

Notes to the Financial Statements

for the Period Ended 31 May 2020

1. Accounting policies

Basis of measurement and preparation

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Intangible fixed assets amortisation policy

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship. Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

ORION MEDTECH LTD C.I.C.

Notes to the Financial Statements for the Period Ended 31 May 2020

2. Employees

	<i>8 months to 31 May 2020</i>	<i>2019</i>
Average number of employees during the period	0	0

ORION MEDTECH LTD C.I.C.

Notes to the Financial Statements

for the Period Ended 31 May 2020

3. Creditors: amounts falling due within one year note

	<i>8 months to 31 May 2020</i>	<i>2019</i>
	£	£
Taxation and social security	12,668	4,766
Other creditors	12,010	10,850
Total	<u>24,678</u>	<u>15,616</u>

COMMUNITY INTEREST ANNUAL REPORT

ORION MEDTECH LTD C.I.C.

Company Number: 11589078 (England and Wales)

Year Ending: 31 May 2020

Company activities and impact

The company has met its objectives to promote high quality healthcare in the UK during the financial period ending 31 May 2020 through the following activities: Establishing a Steering Group with senior clinicians and experts from 7 NHS Hospital Trusts to develop a national registry of metastatic breast cancer treatment in the UK. Working together with the National Institute for Health Research Brain Injury Medtech Cooperative (NIHR Brain MIC) and the Clinical Director of the National Centre for Stereotactic Radiosurgery at Royal Hallamshire Hospital, Orion MedTech has led discussions to establish a prospective database of patients undergoing stereotactic radio surgical therapy (SRS) for cerebral metastases from breast cancer. Its aims are to define current practice and to explore the interaction of systemic anti-cancer therapy with SRS in terms of disease control, survival and complications. Orion MedTech has provided its expertise to the Steering Group without charge, and expects to be able to run a national pilot at no cost to participating NHS centres by June 2021. Providing 60 benchmarking and quality assurance reports to a total of 37 NHS Trusts, which can be used to identify service improvement opportunities and best practice, for the benefit of the specialist services provided by the recipient NHS Trusts. These services include cancer treatment, epilepsy surgery for children and medical implant services to treat hydrocephalus. To maintain sustainability and financial viability, Orion MedTech has worked with the Medicines and Healthcare products Regulatory Agency and manufacturers of medical implants to provide a data analysis service which allows post-market surveillance of medical devices and identification of adverse events related to implanted devices in UK patients. Orion MedTech continues to provide software solutions and support to 37 NHS Trusts, many of which are made available without charge, or at cost.

Consultation with stakeholders

No consultation with stakeholders

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
26 May 2021

And signed on behalf of the board by:

Name: DR Alexis JOANNIDES

Status: Director

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.